In vivo, TENT5A enhances the immunogenicity of the anti-COVID-19 mRNA-based vaccines mRNA-1273 and BNT162b2, but not that of Nuvaxovid, which contains purified spike protein as an antigen. The gene discussed is TENT5A; the disease is COVID-19.